SP-0626: Omics in molecular profiling of tumour hypoxia  by Alsner, J.
S242  2nd ESTRO Forum 2013	
 SYMPOSIUM: HYPOXIA AND RADIOTHERAPY – THE 
STATE OF THE SCIENCE  
  
SP-0626   
Omics in molecular profiling of tumour hypoxia  
J. Alsner1 
1Aarhus University Hospital, Department of Experimental Clinical 
Oncology, Aarhus C, Denmark  
 
The term 'omics' generally refers to fields of studies in biology and 
medicine ending in -omics. The related ending -ome refers to the 
objects of these studies, and implies some sort of totality (e.g. the 
genome is the entirety of the hereditary information in an 
organism). Some of the more popular 'omics' include genomics (except 
for some RNA viruses, this involves studies on DNA), epigenomics 
(studies on chemical changes to DNA and histone proteins), 
transcriptomics (studies on RNA), proteomics (studies on proteins), 
metabolomics (studies on chemical processes involving metabolites), 
pharmacogenomics (studies on the influence of genetic variation on 
drug response), and radiogenomics (studies on the influence of 
genetic variation on radiation-induced normal tissue toxicity). 
Molecular profiling can be used to identify novel targets for 
intervention and for pretherapeutic hypoxic evaluation. There is a 
high degree of heterogeneity in certain tumour sites with respect to 
hypoxia, which can lead to primary resistances to radiotherapy and 
selection of more aggressive tumour phenotypes. The development of 
markers and methods for prediction and proper patient stratification 
is a major research area. Besides molecular profiling, this is often 
addressed using oxygen sensing electrodes or by functional imaging. 
One of the preferred 'omics' for molecular profiling of tumour hypoxia 
is transcriptomics (1). The effect of hypoxia on genome-wide 
transcription levels can be studied in vitro under controlled conditions 
of oxygen tensions, time of exposure, and other environmental 
conditions like extracellular pH. This has led to the development of 
several different gene expression signatures (also known as profiles or 
metagenes). Another approach is to use xenograft models. Finally, 
hypoxia gene expression signatures can be generated by identifying 
candidate genes from in vitro studies and use data from genome-wide 
expression studies on tumour biopsies to analyse and identify 
coexpression networks. In general, and independent on how they have 
been developed, gene expression signatures are associated with poor 
prognosis for the two main cancer types where they have been studied 
most intensely, i.e. head and neck and breast cancer. Recently, one 
of the signatures has also been shown to have predictive value, being 
able to identify patients that benefit from hypoxic modification in a 
randomized trial evaluating the effect of the hypoxic radiosensitizer 
nimorazole (2). Clinical trials on hypoxic radiosensitizers are currently 
being planned, and will hopefully clarify the predictive value of 
hypoxia gene expression signatures. 
Other 'omics' for molecular profiling of tumour hypoxia include 
proteomics and metabolomics. Hypoxia not only affects transcription 
but also translation, and these studies are essential when studying 
signalling pathways and identifying novel targets for intervention, and 
may also provide additional prognostic and predictive value. The 
technologies for genome-wide studies on proteins and metabolites 
have not been as comprehensive and established as for studies on DNA 
and RNA, but with recent technological developments proteomics and 
metabolomics will be increasingly important for molecular profiling of 
tumour hypoxia.  
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In a first part of the talk, state-of-the art methods for non-invasive 
tumour hypoxia imaging using positron emission tomography (PET) will 
be revised. Furthermore, a short overview on currently practised or 
proposed strategies to individualise radiotherapy (RT) based on 
hypoxia PET imaging will be given. 
In a second part, first results of a clinical hypoxia dose painting (HDP) 
carried out in Tübingen trial will be presented. Between 2009 and 
2012, n=21 head and neck cancer (HNC) patients were included into a 
randomized clinical HDP trial. All patients underwent pre-treatment 
[18F]-fluorodesoxyglucose (FDG) PET/CT in addition to dynamic [18F]-
fluoromisonidazole (FMISO) PET/CT imaging. n=16 patients presented 
with a moderate or high level of pre-treatment tumour hypoxia. Those 
were randomized into two different treatment groups: standard IMRT 
(n=8) or HPD consisting of a 10% dose escalation (77 Gy) inside the 
planning target volume of highest order (PTV70) (n=8). Hypoxic 
volumes (HV) were discriminated based on hypoxia and perfusion 
parameters determined by a kinetic analysis of the dynamic FMISO 
PET data. All patients completed pre-treatment imaging examinations 
and RT treatment as planned. Patients randomized into the HDP arm 
did not show increased levels of acute toxicity. After a median follow-
up time of 7 months (0 - 40 months), also no increased levels of late 
toxicities were observed. The mean volume of the PTV was 186.83 ml 
(68.47 - 455.65 ml), whereas the HV had a mean size of 9.37 ml (0 - 
49.17 ml). So far, n=6 local recurrences were observed: 2 in the 
experimental arm and 4 receiving standard IMRT. Technically, the 
integration of dynamic FMISO PET parameters to escalate the dose 
inside the PTV70 was feasible. However, HDP of volumes below a 
critical volume of approximately 2 ml could not be realized due to the 
finite size of dose gradients necessary to increase the dose level by 
10%. 
In a last part of the presentation, the potential of newly available 
hybrid imaging systems combining PET with magnetic resonance 
imaging (PET/MRI) for non-invasive hypoxia imaging will be discussed. 
n=3 patients of the above mentioned study were additionally 
examined with simultaneous PET/MRI including a FMISO PET scan 
approximately 3 h post injection together with a series of diagnostic 
and functional MRI techniques (diffusion weighted, DW and dynamic 
contrast enhanced, DCE). These first clinical FMISO PET/MRI data sets 
hint at a potential correlation of the voxel-based FMISO uptake and 
the local tumour perfusion as measured with DCE-MRI. 
State-of-the-art hypoxia imaging with non-invasive methods is still an 
evolving field of research. Hypoxia imaging using PET/CT and also 
PET/MRI shows a high potential for individualising RT.  
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Tumor hypoxia is a negative prognostic factor in patients treated with 
radiotherapy. This is at least in part because hypoxic cells are 
radiation resistant. Many strategies have consequently been employed 
to overcome the problem of radiation resistant hypoxic cells in the 
clinic. These include the chemical substitution for oxygen with 
hypoxic radiosensitizers or efforts to increase tumor oxygen supply 
with vasodilators and breathing of high-oxygen content gas during 
radiotherapy. Such strategies have proven successful, improving loco-
regional control and survival inpatients with head and neck cancer in 
randomized phase III trials. In spite of this, oxygen modification has 
not entered routine clinical practice in most countries, and we are 
still in need of safe, affordable and practical alternatives to mitigate 
radiation resistance due to tumor hypoxia. A novel class of drugs 
inhibiting mitochondrial activity may represent such an alternative. 
Hypoxia arises distal to blood vessels due to the high oxygen 
consumption of more proximal cells which thereby limit the diffusion 
distance of oxygen in the tumor tissue. Inhibition of oxygen 
consumption by targeting mitochondria can therefore promote 
redistribution of oxygen in tumors and reduce hypoxia. Recent 
promising preclinical data suggest that clinically available inhibitors of 
mitochondrial function are potent tumor radiosensitizers due to their 
ability to reduce the hypoxic fraction.  
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Introduction to the problem: CT was introduced into clinical practice 
in the early 1970s and developing concepts for CT dosimetry attracted 
the interest of many scientists. These efforts finally led to the paper 
by Shope et al. in which the computed tomography dose index (CTDI) 
was introduced. At that time the measurement of CTDI was optimized 
for a narrow CT fan beam geometry, the beam width was usually 
smaller than 10 mm. CTDI measurements are performed with either a 
cylindrical head or body phantom and a 100 mm long pencil ionization 
